• At the present time there are several clinical trial studies

  2021-11-30

  

  At the present time, there are several clinical trial studies being conducted with a variety of indications for pitolisant. Various studies in different phases assess different aspects of pitolisant efficacy and safety in narcoleptic patients (Szakacs et al., 2017) (NCT01800045, NCT02611687, NCT0343

• br Conclusion br Introduction Gastric adenocarcinoma GA is t

  2021-11-30

  

  Conclusion Introduction Gastric adenocarcinoma (GA) is the fifth most commonly diagnosed malignancy and the third most common cause of death due to cancer worldwide. It is a highly aggressive cancer and 5-year survival rate (5YSR) is usually [2], that was grouped GA as intestinal (well differ

• Sonidegib is currently under investigation for the treatment

  2021-11-30

  

  Sonidegib is currently under investigation for the treatment of relapsed/refractory acute leukemia (NCT01826214) [76]. All patients experienced at least 1 AE, including anemia, diarrhea, fatigue, nausea, muscle spasms, decreased appetite, and blood creatine phosphokinase increased. The ongoing phas

• br Results and discussion br Conclusion In summary starting

  2021-11-29

  

  Results and discussion Conclusion In summary, starting from our previous lead DL-Menthol 1, we replaced the 5-nitropyrimidine core with pyrimidopyrimidine to obtain a series of novel compounds as drug candidates of GPR119 agonist for treatment of type 2 diabetes. Some derivatives showed good

• In respect of clinical development Takeda has

  2021-11-29

  

  In respect of clinical development Takeda has pioneered the field with the GPR40 agonist TAK-875 or fasiglifam (Figure 2A), which in phase-II studies decreased HbA1c as efficiently as sulfonylurea without signs of hypoglycemia [24]. This was obtained with surprisingly little effect on systemic insul

• fluoxetine hydrochloride mg Epidemiological studies revealed

  2021-11-29

  

  Epidemiological studies revealed that vitamin D deficiency was associated with a wide range of neuropsychiatric disorders and neurodegenerative diseases, in particular, Alzheimer's and Parkinson's disease (Annweiler et al., 2013; Knekt et al., 2010), dementia and cognitive function impairment (Balio

• L Family Leguminosae widely distributed in tropical and subt

  2021-11-29

  

  L. (Family Leguminosae) widely distributed in tropical and subtropical regions of the world. As a medicinal and edible plant, it is widely used in Asia, especially in China, Korea, Japan and India. It was first recorded in Shen Nong Ben Cao Jing (神农本草经), and was described having the effect of cleari

• In conclusion this is the first study performed

  2021-11-29

  

  In conclusion, this is the first study performed in acute limbic seizure models that shows the ability of DAG to dose-dependently attenuate pilocarpine-induced seizures, albeit at a higher concentration as ghrelin (Portelli et al., 2012b). We also establish that DAG's anticonvulsant mechanism of ac

• FFA expression was also noted to be upregulated

  2021-11-29

  

  FFA4 expression was also noted to be upregulated in eight human CRC cell lines. Compared to two normal colon cell lines with relative one-fold expression of FFA4, CRC cell lines HCT116 (3.5-fold higher), Colo205 (3-fold), Caco-2 (2.2-fold), HT-29 (2.3-fold), RKO (2.8-fold), DLD-1 (2.9-fold), SW480 (

• br Molecular aberrations in the FGFR signaling pathway br

  2021-11-29

  

  Molecular aberrations in the FGFR signaling pathway Non–small cell lung cancer Small cell lung cancer Integrated GDC-0834 australia analysis revealed focal amplification of FGFR1 in 6% of SCLC cases. In another study with PD173074, Pardo et al. used two human SCLC xenograft models, H-510 a

• br Author contributions statement P N Y designed the

  2021-11-29

  

  Author contributions statement P.N.Y. designed the study, analyzed the data and prepared the draft of the manuscript. C.S performed the experiments, analyzed the data and generated Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5, Fig. 6, Fig. 7, Fig. 8. A.K. and S.D. made Supplementary Figs. S1 and S2. D.

• More recently Vismodegib was administered in combination

  2021-11-29

  

  More recently, Vismodegib was administered in combination with Gemcitabine in a pilot clinical trial that enrolled 23 patients affected by metastatic pancreatic adenocarcinoma. This type of malignancy is the most frequent form of pancreas cancer and is ranked in fourth place for cancer mortality in

• br Modulators of the GUCY C cGMP PDEs signaling pathways

  2021-11-29

  

  Modulators of the GUCY2C/cGMP/PDEs signaling pathways for CRC prevention and therapy (pre-clinical and clinical development) Several modulators of the GUCY2C/cGMP/PDEs signaling pathways, including GUCY2C agonists and PDEs inhibitors, have been developed and explored as chemopreventive agents for

• Ikaros utilizes chromatin remodeling to

  2021-11-29

  

  Ikaros utilizes Angiotensin Fragment 1-7 acetate mg remodeling to activate or repress the transcription of its target genes (Su et al., 2004). Ikaros directly associates with histone deacetylases HDAC1 and HDAC2 and can recruit them to the upstream regulatory elements of its target genes (Kim et al

• To apply the recently developed GPR ligands to CNS disorders

  2021-11-29

  

  To apply the recently developed GPR35 ligands to CNS disorders, it is necessary to understand whether GPR35 is expressed by any identified cell types in the Furegrelate sodium salt and whether activation or blockade of this receptor has any consequence on the activity of the neuronal circuitry. To

14459 records 535/964 page Previous Next First page 上5页 531532533534535 下5页 Last page